<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137302</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO 2019-04</org_study_id>
    <nct_id>NCT04137302</nct_id>
  </id_info>
  <brief_title>Administration of Hydrocortisone in Young Healthy Male Volunteers</brief_title>
  <acronym>H-CORT</acronym>
  <official_title>Administration of Hydrocortisone in Young Healthy Male Volunteers: Determination of Biomarkers for Distinguishing Between Local and Systemic Pathways</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French Anti-Doping Agency (AFLD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The misuse of cortisone or hydrocortisone for doping purpose in sport has been widely&#xD;
      reported in the literature, but to date, no formal testing procedure is available and&#xD;
      applicable in an anti-doping laboratory to detect hydrocortisone doping abuse , i.e.,&#xD;
      administration by systemic way.&#xD;
&#xD;
      The investigators therefore propose to identify biomarkers that clearly distinguish between&#xD;
      an authorized local administration of hydrocortisone and a prohibited systemic&#xD;
      administration, by studying the impact of 5-day administration of hydrocortisone per 2&#xD;
      different routes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical research with two groups of ten volunteers one group with 5 days with local&#xD;
      administration (cream, applied to healthy skin) one group with 5 days with systemic route of&#xD;
      administration (per os)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Monocentric, randomized, open-label study&#xD;
Distribution of patients in groups according to a ratio (1:1)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary concentration of cortisol and its metabolites with Gas Chromatography Mass Spectrometry</measure>
    <time_frame>7 days</time_frame>
    <description>Gas Chromatography Mass Spectrometry to study biomarkers urine level at 8 am, 10 am, 8 pm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary concentration of cortisol and its metabolites with Gas Chromatography Mass Spectrometry</measure>
    <time_frame>Day 12</time_frame>
    <description>Gas Chromatography Mass Spectrometry to study biomarkers urine level at 8 am,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary concentration of cortisol and its metabolites with Isotope ratio mass spectrometry t</measure>
    <time_frame>7 days</time_frame>
    <description>Isotope ratio mass spectrometry to study biomarkers urine level at 8 am, 10 am, 8 pm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary concentration of cortisol and its metabolites with Isotope ratio mass spectrometry t</measure>
    <time_frame>Day 12</time_frame>
    <description>Isotope ratio mass spectrometry to study biomarkers urine level at 8 am</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood concentration of cortisol</measure>
    <time_frame>7 days</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am; 10 am, 8 pm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of cortisol</measure>
    <time_frame>Day 12</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of DeHydroEpiAndrostérone</measure>
    <time_frame>7 days</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am; 10 am, 8 pm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of DeHydroEpiAndrostérone</measure>
    <time_frame>day 12</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of Adreno CorticoTrophic Hormone</measure>
    <time_frame>7 days</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am; 10 am, 8 pm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood concentration of Adreno CorticoTrophic Hormone</measure>
    <time_frame>Day 12</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva concentration of cortisol</measure>
    <time_frame>7 days</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay, ) to study cortisol concentration at 8 am; 10 am, 8 pm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva concentration of DeHydroEpiAndrostérone</measure>
    <time_frame>7 days</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay, ) to study cortisol concentration at 8 am; 10 am, 8 pm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva concentration of Adreno CorticoTrophic Hormone</measure>
    <time_frame>7 days</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay, ) to study cortisol concentration at 8 am; 10 am, 8 pm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva concentration of cortisol</measure>
    <time_frame>Day 12</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva concentration of Adreno CorticoTrophic Hormone</measure>
    <time_frame>Day 12</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>saliva concentration of DeHydroEpiAndrostérone</measure>
    <time_frame>Day 12</time_frame>
    <description>Elisa test (enzyme-linked immunosorbent assay) to study cortisol concentration at 8 am</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Anti-doping Campaign, Detection of Hydrocortisone</condition>
  <arm_group>
    <arm_group_label>Topical hydrocortisone administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dermal cream (twice a day, 2.5 g of cream, 1% hydrocortisone during 5 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic hydrocortisone administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tablets (once a day, 50 mg, morning, during 50 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone administration</intervention_name>
    <description>Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments</description>
    <arm_group_label>Systemic hydrocortisone administration</arm_group_label>
    <arm_group_label>Topical hydrocortisone administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male subjects&#xD;
&#xD;
               -  aged 18 to 30 years&#xD;
&#xD;
               -  18 &lt; BMI &lt; 28&#xD;
&#xD;
               -  participating in regular physical activity (3-5 times/week)&#xD;
&#xD;
               -  subjects not on medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        asthmatic subjects or history of respiratory or cardiac pathology; use of corticosteroids&#xD;
        in the past 6 months; high blood pressure; ulcerated lesions of the skin, acne, rosacea;&#xD;
        Infectious state (bacterial, viral, and fungal infections); diabetic subjects; ulcerative&#xD;
        history and other gastrointestinal disorders; lactose allergy; galactose intolerance;&#xD;
        ulcerative colonic pathology; myastenia gravis; live vaccine kidney failure&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AMIOT Virgile, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Regional Center of ORLEANS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional Hospital Center of ORLEANS</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Arlettaz A, Portier H, Lecoq AM, Rieth N, De Ceaurriz J, Collomp K. Effects of short-term prednisolone intake during submaximal exercise. Med Sci Sports Exerc. 2007 Sep;39(9):1672-8.</citation>
    <PMID>17805102</PMID>
  </reference>
  <reference>
    <citation>Buisson C, Mongongu C, Frelat C, Jean-Baptiste M, de Ceaurriz J. Isotope ratio mass spectrometry analysis of the oxidation products of the main and minor metabolites of hydrocortisone and cortisone for antidoping controls. Steroids. 2009 Mar;74(3):393-7. doi: 10.1016/j.steroids.2008.11.001. Epub 2008 Nov 13.</citation>
    <PMID>19056411</PMID>
  </reference>
  <reference>
    <citation>Collomp K, Arlettaz A, Buisson C, Lecoq AM, Mongongu C. Glucocorticoid administration in athletes: Performance, metabolism and detection. Steroids. 2016 Nov;115:193-202. doi: 10.1016/j.steroids.2016.09.008. Epub 2016 Sep 16. Review.</citation>
    <PMID>27643452</PMID>
  </reference>
  <reference>
    <citation>Collomp K, Arlettaz A, Portier H, Lecoq AM, Le Panse B, Rieth N, De Ceaurriz J. Short-term glucocorticoid intake combined with intense training on performance and hormonal responses. Br J Sports Med. 2008 Dec;42(12):983-8. Epub 2007 Nov 29.</citation>
    <PMID>18048433</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hydrocortisone (cortisol)</keyword>
  <keyword>local administration of cortisol</keyword>
  <keyword>systemic administration of cortisol</keyword>
  <keyword>biomarkers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

